Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SRD5A1 | P18405 | 9/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.59 |
| ▸ | FNTA | P49354 | 3/20 | 0.56 |
| ▸ | FNTB | P49356 | 3/20 | 0.56 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482342 | 1.00 | USP2 (0.73) | USP2NPC1L1LMNASRD5A1SRD5A2 | |
| Ethylene SCHEMBL11418142 | 0.89 | NPC1L1 (0.61) | USP2NPC1L1LMNASRD5A1SRD5A2 | |
| SCHEMBL11420729 | 0.89 | NPC1L1 (0.61) | USP2NPC1L1LMNAGPBAR1CYP19A1 | |
| SCHEMBL11416459 | 0.89 | NPC1L1 (0.61) | USP2NPC1L1LMNAGPBAR1CYP19A1 | |
| SCHEMBL11403982 | 0.89 | NPC1L1 (0.61) | USP2NPC1L1LMNAGPBAR1CYP19A1 | |
| Ethylene SCHEMBL11415655 | 0.87 | NPC1L1 (0.59) | USP2NPC1L1LMNAGPBAR1CYP19A1 | |
| SCHEMBL6558718 | 0.86 | GPBAR1 (0.74) | USP2NPC1L1LMNAFNTAFNTB | |
| SCHEMBL29289383 | 0.86 | GPBAR1 (0.74) | USP2NPC1L1LMNAFNTAFNTB | |
| SCHEMBL11415673 | 0.86 | GPBAR1 (0.74) | USP2NPC1L1LMNAFNTAFNTB | |
| Ethylene SCHEMBL11411567 | 0.86 | GPBAR1 (0.66) | USP2NPC1L1LMNAFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376532-B1 | METHOD OF IDENTIFYING MODULATORS OF THE INTERACTION BETWEEN CERTAIN OXYSTEROLS AND EBI2 | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8497075-B2 | Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands | NOVARTIS AG (CH) | 2013-07-30 | — | — | US | disclosed |
| EP-2376532-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243923-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2011-10-06 | — | — | US | disclosed |
| WO-2010066689-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| US-5929062-A | COMBINATION OF ONE OR MORE OXYSTEROLS AND A SUITABLE CARRIER; ANTICHOLESTEROL AGENTS | UNIVERSITY OF WESTERN ONTARIO (CA) | 1999-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110243923-A1 | ORGANIC COMPOUNDS | HAVCR2, DHCR7, NR1H4 | USP2 761/4885NPC1L1 74/4885LMNA 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.